Trelleborg Receives Patent for Dartex Zoned Coatings

The Trelleborg Engineered Coated Fabrics manufacturing facility in Nottingham, England, has received a patent for its Dartex Zoned Coatings®.

Dartex Zoned Coatings® uniquely offer the ability to ‘zone’ different polyurethane coatings on support surface covers used in healthcare and medical applications, allowing a single fabric to perform multiple functions. Inventors of patent number US 11,499,265 B2 are Richard Haxby, Technical Director and Ilias Alexandrakis, Senior Development Project Manager.

Haxby says: “Trelleborg has a long history of developing intellectual property and understands the value of investing in research to help drive innovation in its chosen industries, including healthcare and medical. Dartex Zoned Coatings® technology is revolutionary, making it possible for medical device manufacturers to develop the ultimate support surfaces.”

Alexandrakis, adds: “This is an exciting advancement for the industry. It will mean that medical device manufacturers can streamline their production processes, potentially saving money and bringing products to market more quickly.”

Using patent-pending manufacturing methods, Dartex Zoned Coatings® allows zoning of a support surface cover so that a single cover can have multiple physical and stretch properties across different zones without joins, welds or seams. They incorporate trusted Dartex® polyurethane coating technology from Trelleborg for patient comfort and quality.

The coatings are suitable for multiple healthcare and medical applications, including mattress covers (tops and encasements), moving and handling, positioning devices, specialist medical furniture, theatre tables, trollies and stretchers. Mattress covers can be zoned in harmony with the mattress core.

Find out more about Trelleborg’s Dartex Zoned Coatings® here: https://www.trelleborg.com/engineered-coated-fabrics/industries/healthcare-and-medical/healthcare-and-medical-product-range/dartex-zoned-coatings

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.